Key Points
- Director Luke Evnin sold a large block of Werewolf Therapeutics stock — totaling 358,445 shares between Nov. 28 and Dec. 12 (including 28,009 shares on Dec. 11 at $1.07) for roughly $350,000, leaving him with 2,907,986 shares valued at about $3.11 million (the Dec. 11 sale alone was a 0.95% reduction in his stake).
- Shares trade near $1.10 with a market capitalization of about $53.4 million"Moderate Buy" and an average price target of $7.75, while institutional investors own roughly 64.84% of the stock.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 17,858 shares of the business's stock in a transaction on Friday, December 12th. The shares were sold at an average price of $1.08, for a total transaction of $19,286.64. Following the completion of the sale, the director directly owned 2,890,128 shares in the company, valued at $3,121,338.24. This represents a 0.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Luke Evnin also recently made the following trade(s):
- On Thursday, December 11th, Luke Evnin sold 28,009 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.07, for a total value of $29,969.63.
- On Wednesday, December 10th, Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.06, for a total value of $39,330.24.
- On Tuesday, December 9th, Luke Evnin sold 44,570 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.01, for a total value of $45,015.70.
- On Monday, December 8th, Luke Evnin sold 34,041 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.99, for a total value of $33,700.59.
- On Friday, December 5th, Luke Evnin sold 16,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.97, for a total value of $16,070.96.
- On Thursday, December 4th, Luke Evnin sold 53,416 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.97, for a total value of $51,813.52.
- On Wednesday, December 3rd, Luke Evnin sold 36,726 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.87, for a total transaction of $31,951.62.
- On Tuesday, December 2nd, Luke Evnin sold 38,043 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.89, for a total transaction of $33,858.27.
- On Monday, December 1st, Luke Evnin sold 39,096 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total transaction of $36,750.24.
- On Friday, November 28th, Luke Evnin sold 13,014 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.99, for a total transaction of $12,883.86.
Werewolf Therapeutics Stock Up 0.9%
HOWL stock traded up $0.01 during midday trading on Friday, hitting $1.10. The company's stock had a trading volume of 368,752 shares, compared to its average volume of 481,383. The company's fifty day moving average price is $1.28 and its 200 day moving average price is $1.33. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87. Werewolf Therapeutics, Inc. has a twelve month low of $0.60 and a twelve month high of $2.38. The stock has a market capitalization of $53.39 million, a P/E ratio of -0.68 and a beta of 0.74.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.03. As a group, equities research analysts predict that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.
Wall Street Analysts Forecast Growth
Several research firms have weighed in on HOWL. Bank of America lowered their price target on Werewolf Therapeutics from $8.00 to $7.00 and set a "buy" rating on the stock in a research report on Tuesday, November 18th. JMP Securities dropped their price target on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 21st. Zacks Research cut shares of Werewolf Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, November 21st. Citigroup reaffirmed a "market outperform" rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Werewolf Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $7.75.
Read Our Latest Stock Analysis on HOWL
Institutional Trading of Werewolf Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of HOWL. Charles Schwab Investment Management Inc. grew its stake in Werewolf Therapeutics by 33.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company's stock valued at $93,000 after buying an additional 23,852 shares during the last quarter. MPM Asset Management LLC boosted its holdings in shares of Werewolf Therapeutics by 0.6% during the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company's stock worth $4,189,000 after acquiring an additional 25,688 shares during the period. MPM Bioimpact LLC grew its position in shares of Werewolf Therapeutics by 0.9% in the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company's stock valued at $2,341,000 after purchasing an additional 20,799 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Werewolf Therapeutics in the second quarter valued at approximately $92,000. Finally, Nuveen LLC bought a new position in shares of Werewolf Therapeutics during the first quarter worth approximately $71,000. Institutional investors own 64.84% of the company's stock.
Werewolf Therapeutics Company Profile
(
Get Free Report)
Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
